Equities analysts predict that Sangamo Therapeutics Inc (NASDAQ:SGMO) will report earnings of ($0.23) per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Sangamo Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.37) and the highest estimate coming in at ($0.03). Sangamo Therapeutics reported earnings per share of ($0.26) during the same quarter last year, which suggests a positive year over year growth rate of 11.5%. The firm is expected to announce its next earnings results on Wednesday, August 5th.

On average, analysts expect that Sangamo Therapeutics will report full-year earnings of ($0.16) per share for the current fiscal year, with EPS estimates ranging from ($1.38) to $1.51. For the next year, analysts anticipate that the firm will report earnings of ($1.20) per share, with EPS estimates ranging from ($1.45) to ($0.87). Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that cover Sangamo Therapeutics.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.14). The business had revenue of $13.10 million for the quarter, compared to analyst estimates of $22.73 million. Sangamo Therapeutics had a negative net margin of 89.31% and a negative return on equity of 22.68%. The firm’s quarterly revenue was up 61.7% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.41) earnings per share.

Several research analysts have weighed in on SGMO shares. Zacks Investment Research lowered Sangamo Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, June 13th. Wedbush reaffirmed a “hold” rating and issued a $11.00 target price on shares of Sangamo Therapeutics in a research report on Friday, June 19th. HC Wainwright dropped their target price on Sangamo Therapeutics from $16.00 to $14.00 and set a “buy” rating on the stock in a research report on Monday, June 22nd. BidaskClub lowered Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, June 5th. Finally, ValuEngine lowered Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, June 1st. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the stock. Sangamo Therapeutics currently has an average rating of “Hold” and a consensus target price of $11.50.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Great West Life Assurance Co. Can bought a new stake in shares of Sangamo Therapeutics during the 4th quarter worth about $65,000. Cannell Peter B & Co. Inc. bought a new stake in Sangamo Therapeutics during the 1st quarter valued at approximately $65,000. Bedel Financial Consulting Inc. boosted its stake in Sangamo Therapeutics by 1,538.5% during the 1st quarter. Bedel Financial Consulting Inc. now owns 10,650 shares of the biopharmaceutical company’s stock valued at $68,000 after purchasing an additional 10,000 shares during the period. Norges Bank bought a new stake in Sangamo Therapeutics during the 4th quarter valued at approximately $84,000. Finally, AlphaCrest Capital Management LLC bought a new stake in Sangamo Therapeutics during the 4th quarter valued at approximately $85,000. Institutional investors own 52.92% of the company’s stock.

NASDAQ:SGMO traded up $0.04 during trading hours on Tuesday, hitting $8.77. 1,634,000 shares of the company’s stock traded hands, compared to its average volume of 2,356,573. The company has a debt-to-equity ratio of 0.10, a quick ratio of 5.98 and a current ratio of 5.98. Sangamo Therapeutics has a twelve month low of $4.81 and a twelve month high of $13.33. The stock’s fifty day moving average price is $10.47 and its two-hundred day moving average price is $8.39. The firm has a market cap of $1.23 billion, a P/E ratio of -10.57 and a beta of 2.25.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation.

Recommended Story: What is Net Asset Value (NAV)?

Get a free copy of the Zacks research report on Sangamo Therapeutics (SGMO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.